Mgat5 - Phost'in

02/10/2025

Press release

Biotech, Clinical, Clinical Development, Drug Discovery, ESMO, ESMO 2025, ESMO2025, France2030, Funding, Glycosylation, GnT-V, MASH, Mgat5, N-glycosylation, NASH, Oncology, POSTER, PUBLICATION, small molecules

Phost’in Therapeutics and the Gianni Bonadonna Foundation To Present First Clinical Data on PhOx430, a First-In-Class GnT-V Inhibitor, at ESMO 2025

Montpellier, France and Milan, Italy – October 2025, 2nd